NuCana PLC
NCNA0.046USD
+0.007+17.39%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
278.93KMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über NuCana PLC Unternehmen
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Unternehmensinformationen
BörsenkürzelNCNA
Name des UnternehmensNuCana PLC
IPO-datumSep 28, 2017
CEO- -
Anzahl der mitarbeiter20
WertpapierartDepository Receipt
GeschäftsjahresendeSep 28
AddresseLochside House
StadtEDINBURGH
BörseNASDAQ Capital Market Consolidated
LandUnited Kingdom
PostleitzahlEH12 9DT
Telefon4401313571111
Websitehttps://www.nucana.com/
BörsenkürzelNCNA
IPO-datumSep 28, 2017
CEO- -
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Adam George
Mr. Adam George
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ian Webster
Mr. Ian Webster
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Sofinnova Investments, Inc
0.05%
Abingworth Management Limited
0.03%
Baader Bank AG
0.03%
Schonfeld Strategic Advisors LLC
0.01%
Acadian Asset Management LLC
0.01%
Other
99.87%
Aktionäre
Aktionäre
Anteil
Sofinnova Investments, Inc
0.05%
Abingworth Management Limited
0.03%
Baader Bank AG
0.03%
Schonfeld Strategic Advisors LLC
0.01%
Acadian Asset Management LLC
0.01%
Other
99.87%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
0.09%
Investment Advisor/Hedge Fund
0.04%
Hedge Fund
0.01%
Investment Advisor
0.01%
Other
99.85%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
51
579.39K
0.15%
+67.06K
2025Q1
52
492.36K
2.30%
-26.46K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
2023Q1
81
667.89K
31.87%
-504.63K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Sofinnova Investments, Inc
199.52K
0.05%
+199.52K
--
Feb 14, 2025
Abingworth Management Limited
133.33K
0.03%
--
--
Apr 18, 2025
Baader Bank AG
10.03K
0%
+10.03K
--
Mar 31, 2025
Schonfeld Strategic Advisors LLC
44.77K
0.01%
-300.00
-0.67%
Mar 31, 2025
Acadian Asset Management LLC
38.32K
0.01%
-4.09K
-9.65%
Mar 31, 2025
XTX Markets LLC
20.16K
0.01%
+20.16K
--
Mar 31, 2025
Glass Jacobson Wealth Advisors
15.00K
0%
--
--
Dec 31, 2024
Griffith (Hugh S)
10.60K
0%
--
--
Dec 31, 2024
LUNIS Vermögensmanagement AG
8.90K
0%
-1.00
-0.01%
Sep 30, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Datum
Art
Verhältnis
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
